PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice

Journal of Controlled Release

Volumn 116, Issue 3, 2006, Pages 330-336

  Okuda, Tatsuya ^a,b   Kawakami, Shigeru ^a   Akimoto, Naomi ^a   Niidome, Takuro ^c   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Japan Association for the Advancement of Medical Equipment   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Drug carrier; EPR effect; Lysine dendrimers; PEGylation; Tumor targeting

Indexed keywords

BIOLOGICAL ORGANS; BIOSYNTHESIS; DENDRIMERS; TISSUE; TUMORS;

ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT; LYSINE DENDRIMERS; TUMOR TARGETING;

CONTROLLED DRUG DELIVERY;

DENDRIMER; DRUG CARRIER; DRUG DERIVATIVE; LYSINE DERIVATIVE; POLYETHYLENE GLYCOL 10 SIXTH GENERATION LYSINE DENDRIMER; POLYETHYLENE GLYCOL 76 SIXTH GENERATION LYSINE DENDRIMER; SIXTH GENERATION LYSINE DENDRIMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD FLOW; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; DRUG SYNTHESIS; DRUG TARGETING; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR;

ANIMALS; DENDRIMERS; DRUG CARRIERS; INJECTIONS, INTRAVENOUS; LIVER; LYSINE; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS; POLYETHYLENE GLYCOLS; SPLEEN; TISSUE DISTRIBUTION;

EID: 34249934825     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.09.012     Document Type: Article

References (28)

1. James N.D., Coker R.J., Tomlinson D., Harris J.R., Gompels M., Pinching A.J., and Stewart J.S. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol. (R. Coll. Radiol.) 6 (1994) 294-296
2. Alberts D.S., and Garcia D.J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54 (1997) 30-35
3. Esfand R., and Tomalia D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6 (2001) 427-436
4. Stiriba S.E., Frey H., and Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew. Chem., Int. Ed. 41 (2002) 1329-1334
5. Kukowska-Latallo J.F., Candido K.A., Cao Z., Nigavekar S.S., Majoros I.J., Thomas T.P., Balogh L.P., Kahn M.K., and Baker Jr. J.R. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65 (2005) 5317-5324
6. Yoo H., and Juliano R.L. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res. 28 (2000) 4225-4231
7. Choi J.S., Nam K., Park J.Y., Kim J.B., Lee J.K., and Park J.S. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine. J. Control. Release 99 (2004) 445-456
8. Wada K., Arima H., Tsutsumi T., Hirayama F., and Uekama K. Enhancing effects of galactosylated dendrimer/alpha-cyclodextrin conjugates on gene transfer efficiency. Biol. Pharm. Bull. 28 (2005) 500-505
9. Kobayashi H., Kawamoto S., Star R.A., Waldmann T.A., Tagaya Y., and Brechbiel M.W. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res. 63 (2003) 271-276
10. Kobayashi H., Jo S.K., Kawamoto S., Yasuda H., Hu X., Knopp M.V., Brechbiel M.W., Choyke P.L., and Star R.A. Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure. J. Magn. Reson. Imaging 20 (2004) 512-518
11. 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Release 65 (2000) 133-148
12. Ohsaki M., Okuda T., Wada A., Hirayama T., Niidome T., and Aoyagi H. In vitro gene transfection using dendritic poly(L-lysine). Bioconjug. Chem. 13 (2002) 510-517
13. Okuda T., Sugiyama A., Niidome T., and Aoyagi H. Characters of dendritic poly(L-lysine) analogues with the terminal lysines replaced with arginines and histidines as gene carriers in vitro. Biomaterials 25 (2004) 537-544
14. Okuda T., Kawakami S., Maeie T., Niidome T., Yamashita F., and Hashida M. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J. Control. Release 114 (2006) 69-77
15. Fields C.G., Lloyd D.H., Macdonald R.L., Otteson K.M., and Noble R.L. HBTU activation for automated Fmoc solid phase peptide synthesis. Pept. Res. 4 (1991) 95-101
16. Hnatowich D., Layne W.W., and Childs R.L. The preparation and labeling of DTPA-coupled albumin. J. Appl. Radiat. Isot. 12 (1982) 327-332
17. Skoog B. Determination of polyethylene glycols 4000 and 6000 in plasma protein preparations. Vox Sang. 37 (1979) 345-349
18. Duncan J.R., and Welch M.J. Intracellular metabolilsm of indium-111-DTPA-labeled receptor targeted proteins. J. Nucl. Med. 34 (1993) 1728-1738
19. 125I. Effect of labeling on distribution and excretion of radioactivity in rats. J. Pharm. Sci. 88 (1999) 577-585
20. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., and Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 105 (2005) 305-317
21. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986) 6387-6392
22. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., Okano T., Sakurai Y., and Kataoka K. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 74 (2001) 295-302
23. Lukyanov A.N., Heartner W.C., and Torchilin V.P. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J. Control. Release 97 (2004) 187-193
24. Bae Y., Nakanishi N., Fukushima S., Koyama H., Yasuhiro M., and Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release properties: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16 (2005) 122-130
25. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., and Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumor in vivo. Pharm. Res. 18 (2001) 1042-1048
26. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., Okuwa M., Matsumoto S., Miyata Y., Ohkura H., Chin K., Baba S., Yamao T., Kannami A., Takamatsu Y., Ito K., and Takahashi K. Phase I and phamacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15 (2004) 517-525
27. Dams E.T., Laverman P., Oyen W.J., Storm G., Scherphof G.L., van Der Meer J.W., Corstens F.H., and Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 292 (2000) 1071-1079
28. Ishida T., Ichikawa T., Ichihara M., Sadzuka Y., and Kiwada H. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J. Control. Release 95 (2004) 403-412